

# BREAKING NEW GROUND WITH CDK4/6 INHIBITORS:

Case-based discussions on treatment decisions in HR+/HER2- breast cancer



Thursday,  
16 May 2024



12:45–13:45 CEST



hub27 – Messe Berlin  
Frankfurt Hall,  
Berlin, Germany

## Our esteemed faculty:



**Prof. Dr. Wolfgang Janni, MD, PhD**  
Professor and Chair, Department  
of Obstetrics and Gynecology,  
University of Ulm  
Ulm, Germany



**Dr. Carlos H. Barrios, MD**  
Director of LACOG – Latin American  
Clinical Oncology Research Group  
Oncoclínicas Group in Porto Alegre,  
Brazil



**Dr. Stephanie L. Graff, MD, FACP**  
Director, Legorreta Cancer Center at  
Brown University, United States

## Agenda:

- Unmet Need in HR+/HER2- Early Breast Cancer
- Exploring CDK4/6 Inhibitor Clinical Data in HR+/HER2- Early Breast Cancer
- Reviewing the Treatment Landscape for HR+/HER2- ABC
- Analyzing First-Line CDK4/6 Inhibitor Clinical Data in HR+/HER2- ABC
- Closing and Key Takeaways

This scientific program and/or material was developed for use outside of the US, intended for non-US HCPs licensed to prescribe medicine, and is to be used in accordance with local laws and regulations. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the Summary of Product Characteristics (SmPC) or product information approved in your local country. This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities.